John Dingell news from FiercePharma
News
House, Senate hook up on DTC ads
DTC ads may have performed a minor miracle. The U.S. House and Senate appear to be poised to work together. Yes, these perennial competitors could join forces on investigating consumer advertising... Read more...
Peto bristles at Vytorin-cancer questions
Sir Richard Peto takes umbrage at the idea that he might skew a statistical analysis to benefit a drugmaker. The eminent Oxford statistician, as you know, recently weighed in on a study that seemed... Read more...
FDA probes Vytorin cancer risk
Yesterday, a study appeared to clear statins of their possible link to cancer. But today, the FDA says it's... Read more...
Congress wants Vytorin analysis
Congress wants to get its hands on the latest Vytorin data. The House Energy and Commerce Committee is... Read more...
House votes to treat tobacco as a drug
If the U.S. House gets its way, the FDA soon may have even more power -- to regulate tobacco as a drug. Reps voted overwhelmingly to charge the agency with overseeing the tobacco industry, in spite... Read more...
Grassley, Dingell plan FDA renovation
A pair of FDA critics, Rep. John Dingell (D, MI) and Sen. Chuck Grassley (R, IA), are making it a major priority to overhaul the... Read more...
Did FDA know Ranbaxy meds might be off?
Last week, amid all the brouhaha over the did-Ranbaxy-sell-substandard-meds probe, we reported that Congress had launched an investigation of its own -- into just how the FDA handled those... Read more...
Pharma aims to forestall DTC legislation
Pharma industry lawyers descended on the U.S. capital this week to meet with House Energy and Commerce Committee staffers, hoping to forestall legislation that could limit drugmakers' ability to... Read more...
FDA handed out $35M in bonuses
The FDA finds itself in the line of Congressional fire on two different issues today. One, the agency is taking some heat for the $35 million in incentive pay it handed out last fiscal year, a 29... Read more...
Drugmakers to delay new-drug ads
There's a waiting period for marriage licenses, IPOs, and flood insurance -- and now, drug advertising. Several big drugmakers called on the Congressional carpet for their advertising campaigns now... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
